TICKERNERD
Menu
DRMADRMAHealthcare · Biotechnology

DRMA Stock Forecast: Dermata Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.63
+14.79% on the day

The 1 Wall Street analysts covering Dermata Therapeutics, Inc. hold a median 12-month price target of $4 — +145.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.7M
Ticker Nerd rank
29 / 100
Median analyst target
$4.00
Analysts covering
1
Revenue$0.0
Operating income−$1.9M
Net income−$1.8M
Free cash flow−$2.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.6%
1M
+23.5%
YTD
−29.7%
1Y
−70.3%
From 52W high
−72.4%
From 52W low
+51.6%
$1.08
$5.91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DRMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dermata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Revisions
86
Growth
49
Accruals
49
Issuance
23
Momentum
21
Volatility
20
Quality
6
Value
6

Size (96): Smaller than most of the companies we track.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DRMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26DRMAHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +145.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2025Maxim GroupMaintainsBuy$30 → $10
21 May 2025Maxim GroupMaintainsBuy—
21 Aug 2024Maxim GroupMaintainsBuy—
23 Mar 2023Maxim GroupMaintainsBuy—
21 Sept 2021Brookline CapitalInitiatesBuy$14
14 Sept 2021Maxim GroupInitiatesBuy$9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRMA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DRMA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Dermata Therapeutics, Inc. returned −70.3% against +19.6% for the S&P 500, dividends included.

DRMA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26DRMAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DRMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Dermata Therapeutics, Inc. (DRMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
1.7×

Cheaper than 54% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−183.9%

Higher than 8% of US stocks

Return on assets
−89.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dermata Therapeutics, Inc. (DRMA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dermata Therapeutics, Inc. has a market value of $5.7M and an enterprise value of $1.3M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$7.1M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$8.3M.

  • Shares outstanding: 4.0M.

  • Trailing P/E: 0.1×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Dermata Therapeutics, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

DRMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DRMADermata Therapeutics, Inc.$5.7M
29
PMCBPharmaCyte Biotech, Inc.$5.7M
39
CVKDCadrenal Therapeutics, Inc.$5.7M
28
PCSAProcessa Pharmaceuticals, Inc.$5.8M
22
CLGNCollPlant Biotechnologies Ltd.$5.9M
35
BRTXBioRestorative Therapies, Inc.$5.5M
8
PULMPulmatrix, Inc.$5.5M
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dermata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DRMA news & analysis

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Accesswire · 21 Aug 2026positive

Dermata Therapeutics announced that preorders for its first direct-to-consumer skincare product, Tome Foundational Treatment, a once-weekly topical mask, are now open at www.tomeskincare.com. The company expects to begin shipping orders on August 25, 2026, ahead of the product's commercial launch.

Why it matters — A DRMA watcher would care because this marks the commercial launch of the company's first direct-to-consumer skincare product, a key milestone in expanding Dermata's market presence beyond its therapeutic pipeline.

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Accesswire · 17 Aug 2026neutral

Dermata Therapeutics announced it has entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, selling approximately 2,293,608 shares of common stock (or pre-funded warrants) with series E and series F warrants at a purchase price of $1.46 per share. The company expects $3.4 million upfront, with up to about $6.7 million in additional gross proceeds if all warrants are exercised in full.

Why it matters — This financing could provide Dermata with additional capital to fund its operations, and the potential full exercise of the warrants could bring further proceeds to the company.

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Accesswire · 11 Aug 2026positive

Dermata Therapeutics provided a corporate update and reported financial results for the second quarter ended June 30, 2026. The company announced the expected August 25, 2026 launch of its first commercial product, Tome™ Foundational Treatment, and noted it recently introduced the Tome brand at a beauty and wellness show in Las Vegas.

Why it matters — The announcement marks Dermata's transition toward a commercial-stage, direct-to-consumer skincare company with a firm launch date for its first product, a key development for DRMA watchers.

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Accesswire · 5 Aug 2026positive

On August 5, 2026, Dermata Therapeutics announced that Tome Foundational Treatment, its first direct-to-consumer skincare product, is planned to launch on August 25, 2026. Those on the waitlist at tomeskincare.com will get early access to preorder, marking the company's first commercial product launch.

Why it matters — This launch represents a milestone for DRMA as it moves toward becoming a consumer-focused skincare company that generates revenue.

FAQ

Frequently asked questions about DRMA stock

What is the DRMA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Dermata Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRMA stock a buy right now?

Of the 1 analysts covering Dermata Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dermata Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRMA?

As at 22 Aug 2026, Dermata Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will DRMA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +145.4% from the last close, and Ticker Nerd's factor model ranks Dermata Therapeutics, Inc. 29 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRMA stock forecast for 2030?

No analyst covering Dermata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has DRMA stock performed over the past year?

Dermata Therapeutics, Inc. returned -70.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dermata Therapeutics, Inc. do?

Dermata Therapeutics Inc. is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for medical skin diseases and aesthetic applications.

What is the latest news on DRMA?

The most recent item we track (Accesswire, 21 Aug 2026): "Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch". Dermata Therapeutics announced that preorders for its first direct-to-consumer skincare product, Tome Foundational Treatment, a once-weekly topical mask, are now open at www.tomeskincare.com. The company expects to begin shipping orders on August 25, 2026, ahead of the product's commercial launch.

Company

About Dermata Therapeutics, Inc.

Dermata Therapeutics Inc. is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for medical skin diseases and aesthetic applications. Its lead product candidate, XYNGARI, is in Phase 3 clinical studies for moderate-to-severe acne and has completed Phase 1b proof-of-concept trials for mild-to-moderate psoriasis. The company is also advancing DMT410, which has completed Phase 1b proof-of-concept trials for axillary hyperhidrosis and aesthetic skin conditions, utilizing its proprietary Spongilla technology platform for intradermal delivery, including topical botulinum toxin. Dermata Therapeutics Inc. leverages this technology across dermatologic treatments for conditions like acne, psoriasis, rosacea, and seborrheic dermatitis, aiming to deliver innovative once-weekly topical therapies. It maintains clinical trial collaborations to evaluate combinations such as XYNGARI with botulinum toxin products. Founded in 2014 and headquartered in San Diego, California, Dermata Therapeutics Inc. plays a key role in advancing targeted dermatology solutions in the biotechnology sector.

CEO Mr. Gerald T. Proehl · 9 employees · United States · https://www.dermatarx.com